Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vicarious Surgical Inc. RBOT OTC

Other OTC • Healthcare • Medical - Devices • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$8.75
+1150%

Vicarious Surgical Inc. (RBOT) is a Medical - Devices company in the Healthcare sector, currently trading at $0.70. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is RBOT = $9 (+1150% upside).

Net income is $50M (loss), growing at -482.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $8M against $10M equity (Debt-to-Equity (D/E) ratio 0.79, moderate). Current ratio is 2.97 (strong liquidity). Debt-to-assets is 39.8%. Total assets: $20M.

Analyst outlook: 2 / 5 analysts rate RBOT as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$8.75
▲ 1150% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Vicarious Surgical Inc., the average price target is $8.75, with a high forecast of $10.50, and a low forecast of $7.00.
Highest Price Target
$10.50
Average Price Target
$8.75
Lowest Price Target
$7.00

RBOT SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RBOT

✓
VALUE Pass
100/100
RBOT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $9, implying +1185.7% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
RBOT: +0%/yr revenue is, -482.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
RBOT: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
75/100
Balance sheet RBOT: Debt-to-Equity (D/E) ratio 0.79 (moderate), Current ratio is 2.97 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
RBOT: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 2 / 5 analysts rate RBOT as buy (40%). Analyst consensus target is $9 (+1185.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.27-13.746
Volume35.09K
Avg Volume (30D)66.87K
Market Cap$4.53M
Beta (1Y)1.82
Share Statistics
EPS (TTM)-8.45
Shares Outstanding$5.94M
IPO Date2020-09-04
Employees123
CEOStephen From
Financial Highlights & Ratios
Gross Profit$-1.43M
EBITDA$-49.54M
Net Income$-50.18M
Operating Income$-50.97M
Total Cash$9.79M
Total Debt$7.79M
Net Debt$5.22M
Total Assets$19.58M
Price / Earnings (P/E)-0.1
Analyst Forecast
1Y Price Target$8.75
Target High$10.50
Target Low$7.00
Upside+1,150.0%
Rating ConsensusHold
Analysts Covering5
Buy 40% Hold 60% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS92561V2088

Price Chart

Track all markets on TradingView
RBOT
Vicarious Surgical Inc. ↗  ·  Other OTC
Healthcare • Medical - Devices
0.27 52WK RANGE 13.75

People Also View

NUVA
NUVA
NuVasive, Inc.
$39.75
-2.24%
 HSKA
HSKA
Heska Corporation
$119.99
+0.00%
 CNMD
CNMD
CONMED Corporation
$39.44
-0.73%
 FNA
FNA
Paragon 28, Inc.
$13.09
+0.00%
 BVS
BVS
Bioventus Inc.
$10.56
+6.56%
 SIBN
SIBN
SI-BONE, Inc.
$14.49
+0.42%
 CTKB
CTKB
Cytek Biosciences, Inc.
$4.69
+1.52%
 NPCE
NPCE
NeuroPace, Inc.
$15.61
+1.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message